GLP-1 Receptor Agonism
Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that acts on GLP-1 receptors throughout the body to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying (reducing food intake), and act centrally on appetite-regulating brain circuits. GLP-1 receptor agonists have been a major drug class in T2D management since the mid-2000s. Tirzepatide activates GLP-1 receptors as part of its dual mechanism, contributing both to its glucose-lowering efficacy and to its gastrointestinal side effects (nausea, vomiting, diarrhoea — mediated partly via gastric emptying slowing and central GLP-1 effects).
The cardiovascular benefit of GLP-1 receptor agonism has been established independently for semaglutide (SUSTAIN-6), liraglutide (LEADER), and dulaglutide (REWIND) in dedicated CV outcome trials. Tirzepatide has not yet completed a dedicated cardiovascular outcomes trial; SURPASS-4 provided suggestive but underpowered data (MACE HR 0.74, 95% CI 0.51–1.08 vs insulin glargine). The SURPASS-CVOT trial was ongoing as of late 2024.
Ontology GLP-1 Receptor Agonism [mechanism_of_action] Tirzepatide GLP-1 Receptor Agonism [relates] GIP Receptor Agonism GLP-1 Receptor Agonism [may_explain] HbA1c Reduction GLP-1 Receptor Agonism [may_explain] Nausea and Vomiting Risk GLP-1 Receptor Agonism [relates] Semaglutide GLP-1 Receptor Agonism [relates] Cardiovascular Risk
Mechanism Evidence
- Mechanism: GLP-1 → insulin secretion (glucose-dependent), glucagon suppression, gastric emptying delay, appetite suppression (central)
- Clinical claim it may support: HbA1c reduction, weight loss, reduced post-meal glucose, cardiovascular benefit
- Direct evidence: Multiple dedicated CV outcome trials for other GLP-1 RAs; mechanism well-established
- Indirect evidence: Tirzepatide’s GLP-1 component assumed to drive class-consistent cardiovascular and appetite effects
- What should not be inferred: GLP-1 mechanism alone does not explain tirzepatide’s superiority over semaglutide — that requires GIP co-agonism explanation
Connections
- Tirzepatide — mechanism_of_action
- GIP Receptor Agonism — relates (synergistic)
- Semaglutide — relates (pure GLP-1 RA comparator)
- Nausea and Vomiting Risk — may_explain
- Cardiovascular Risk — relates